A decline in cognitive function should lead to a change in disease-modifying therapy -Commentary
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Cognitive impairment (CI) in multiple sclerosis (MS) is finally being given the profile and importance its impact warrants. The last two decades have seen a stream of research addressing some key issues in the field: documenting CI in different MS subtypes, its functional impact and prognostic role; developing brief assessment tools that can be incorporated in everyday patient assessment; improving our knowledge of the mechanisms underpinning cognitive changes and compensatory mechanisms and, finally, testing the potential for therapeutic interventions. Importantly, neuropsychological tests are increasingly utilized as secondary end-points in clinical trials of disease-modifying treatments, or primary targets for symptomatic therapies and cognitive rehabilitation. 1, 2 Cognitive decline may develop as a result of gradual progression related to neurodegeneration and brain atrophy, or of acute disease activity in the context of disease relapses. 3 This 'acute' decline in cognitive performance is often followed by incomplete recovery, thus contributing to the burden of cognitive disability in the long run.
Due to the above considerations, Dr Weinstock Guttman argues that cognitive decline should be included in the spectrum of disease activity and definition of clinical stability, acitivity and progression: therefore, it would clearly deserve consideration in therapeutic decision-making. 4 However, Dr Portaccio discusses a series of issues that may hinder the definition of CI and interpretation of cognitive changes over time. 5 In particular, there is no consensus in the literature as to the tests used to detect CI, the severity of impairment required for the diagnosis, the breadth of the deficit, how to take into account practice effects and potential confounders, what is the 'clinical meaningfulness' of test scores, and if adverse impact on activities of daily life should be required for the diagnosis. One might consider the diagnostic criteria for neurocognitive disorder formalized under the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, 6 wherein cognitive domains are specified, the defect must be apparent to the patient or observer, and there is some documented impact on daily living activities. At present, the validity of these standards for the MS population is largely unknown. Clearly, both positions hold some valid arguments: therefore, where we are and what is needed to fill perceived gaps in knowledge?
First, the symbol digit modalities test (SDMT), an extensively validated test of information processing speed, can represent one possible exception to the above limitations. For the SDMT, a 4-point or 10% decrease in scores is considered a benchmark of clinically meaningful cognitive test values or change in test values, with employment status often used as an objective anchor. 7 As more clinical trial data with SDMT are going to be presented, in the next future we will be enabled to consider whether SDMT decline is indicating suboptimal treatment response and should therefore lead to a change in disease-modifying therapy.
Furthermore, in longitudinal studies, brief cognitive assessment at baseline of all newly diagnosed patients would be of critical importance. This would support accurate judgement of decline from previous function, clinically meaningful changes which would be important for monitoring cognitive disability progression and potentially evaluating treatment efficacy. Finally, we strongly advocate the need for an international, multi-disciplinary endeavour to develop evidencebased guidelines in order to uniform criteria for assessment and diagnosis of cognitive impairment in MS.
In conclusion, cognitive monitoring holds promise as a useful tool for disease surveillance and therapeutic choice. However, some work still needs to be done in the field.
That being said, in their 'real life' experience, clinicians can encounter MS patients who undoubtedly exhibit cognitive difficulties. While waiting for the solution of these issues, available evidence provides clinicians a few cues to include the patient cognitive status among criteria for deciding the appropriate therapeutic strategy/changes in strategy, which necessarily implies expert integration of information pertaining to the disease, treatment and patient characteristics.
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